We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Urinary Biomarkers Perform Better Than Serum Biomarkers in Detection of Specific Diseases

By LabMedica International staff writers
Posted on 02 Nov 2023

The focus in biomarker research has largely been on blood-based markers. More...

Yet, blood markers don't provide a complete picture of clinically relevant indicators. As a result, urine has proved to be a significant and additional source of information for diagnosis. Its diagnostic power, especially for certain conditions, is gaining recognition, sometimes even surpassing that of blood biomarkers. Now, a new study has shed light on the enhanced ability of urinary biomarkers to detect diseases compared to plasma biomarkers.

The study by a group of researchers, including scientists from the Shanghai Changzheng Hospital (Shanghai, China), has revealed that urine biomarkers might be better than serum biomarkers at detecting some illnesses. Blood is a complex mix that remains fairly stable due to the body's homeostatic mechanisms. Urine, on the other hand, varies more because it is a byproduct of kidney filtration and does not need to maintain a stable state. This variability means it can indicate changes occurring in the body more accurately.

During urine production in the kidney's nephrons, biomarkers specific to the urinary system can become more concentrated than in blood. Smaller molecules that aren't reabsorbed after the kidney's filtration become more concentrated in the urine, making them easier to identify. The simplicity and non-invasive nature of collecting urine also make it appealing for biomarker research. Plus, proteins in urine can be preserved for a long time without degrading. Despite these advantages, the researchers recognize hurdles like standardizing urine biomarker tests and expanding the range of illnesses detectable through urine.

“The direct association between urine and the urinary system positions it as a prime area for discovering biomarkers, particularly in the context of urological diseases,” said Dr. Cheng Xue from the Shanghai Changzheng Hospital. “A key takeaway from our findings is the potential for a combined approach, leveraging both urinary and serum biomarkers for a more holistic and personalized strategy for disease diagnosis and management.”

Related Links:
Shanghai Changzheng Hospital


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.